Company Active LTD

Company profile

Atdbio Limited

UK company 05303632, incorporated on 3 December 2004.

ATDBio

Atdbio Limited is a UK company with status Active founded in 2004 based in Wales.

Company number
05303632
Incorporated
3 Dec 2004
Companies House status
Active

Company identity

Founded / incorporated
3 December 2004

Company number 05303632

Verify at Companies House
Legal name
ATDBIO LIMITED
Company type
Private Limited Company
Region
Wales
Registered address
IST HOUSE DISTRIBUTION WAY
DYFFRYN INDUSTRIAL ESTATE
YSTRAD MYNACH
HENGOED
WALES
CF82 7TS
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Atdbio Limited
CRN 05303632
2
Direct and ultimate controller
1000976663
CRN 1000976663

Company events

Reference milestones and recent Companies House filing stream events.

5 events
17 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

03 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

03 Dec
2004

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2013
Funded years
2013, 2020, 2021
Age at first award
8 years

Projects

2021 Collaborative R&D Lead participant

Improved oligonucleotide synthesis for faster, more accurate COVID-19 testing

1 Mar 2021 to 28 Feb 2022

Awarded
£168,130
Total cost £168,130

Testing people to find out whether they are infected with coronavirus is important in order to get them treated properly if they do test positive, and to keep the virus under control in the population. Programmes such as the UK Government's Test and Trace scheme work out whether the virus has infected someone by assessing whether its genetic material is p...

2020 Study Lead participant

Advanced Oligonucleotide Capture Beads

1 Jul 2020 to 31 Dec 2021

Awarded
£188,199
Total cost £268,856

Single-cell RNA sequencing (scRNA-Seq) techniques are emerging as a tool that can support unprecedented cancer diagnostics. scRNA-Seq techniques are critical for evaluating tumour heterogeneity at a single-cell level, providing rich data about the varying expression of genes within the 3D tumour environment. This feat is currently unobtainable using the w...

2013 EU-Funded Lead participant

INGA

1 Sep 2013 to 31 Aug 2016

Awarded
£249,025
Total cost £498,050

Flexmers are next generation aptamers and provide a novel alternative to drug compounds. To enable a very quick and efficient process for flexmer development, ATDBio and Biaffin will combine their expertise to create an integrated drug discovery pipeline for flexmers.

Product types

Collaborative R&D EU-Funded Study